Pfizer Faces Swelling MDL Over Bextra, Celebrex

Law360, New York (September 12, 2007, 12:00 AM EDT) -- Thirty civil actions from various district courts have flooded in to the California federal court presiding over the multidistrict litigation against Pfizer Inc. concerning the alleged health risks associated with the drug maker's anti-inflammatory drugs Bextra and Celebrex.

Despite the rash of dismissals from the multidistrict litigation, 30 cases were transferred earlier this month to the U.S. District Court for the Northern District of California for coordinated or consolidating pretrial proceedings, bringing the total number of transferred actions to 1,140 suits as of Sept. 6, according...
To view the full article, register now.